• About Us
  • Company Overview
  • Leadership
  • Investors
  • Strategic Alliances
  • Contacts
  • FibroGen Europe
• Clinical
  • Current Trials
• Research & Development
  • Hypoxia-Inducible Factor
    HIF Biology

     

    HIF-PHI Therapy

     

    Anemia

     

    Cytoprotection/Inflammation
  • Connective Tissue Growth Factor
    CTGF Biology

     

    Anti-CTGF Therapy

     

    Chronic Kidney Disease

     

    Fibrotic Disease

     

    Cancer
  • Recombinant Human Collagen & Gelatin
• News & Events
  • Publications
  • Press Releases
  • Events
  • Email Sign up
• Careers
  • Job Search
  • Notice to Search Firms and Recruiters

Dermal Filler

Dermal augmentation is a rapidly growing market

Injectable dermal fillers are part of a growing market segment known as "Nonsurgical Cosmetic Procedures". According to the American Society for Aesthetic Plastic Surgery (ASAPS), there were over 9.6 million nonsurgical cosmetic procedures performed in 2007, a 754% increase from (1.1 million procedures in) 1997.

According to a recent survey by ASAPS, there were approximately 2 million dermal filler procedures in 2006, a 25% increase from 2005. Until 2003, collagen injections (bovine type I collagen) were the market leader among dermal fillers, and among the top five non-surgical procedures performed. However, bovine collagen requires a skin test to screen out the approximately 3-5% of persons who are allergic to this cow-derived material. Fillers based on hyaluronic acids, which do not require a skin test, were introduced in 2003 and gained market acceptance to take nearly 80% of the 2006 dermal filler market, largely because allergy skin testing is not required and because of the perception that hyaluronic acids persist longer than traditional collagen.

FibroGen believes there is a significant need and opportunity for a safe and more effective product in the dermal filler market and is exploiting its proprietary recombinant collagen technology to develop dermal filler products to answer unmet market needs specifically in the area of handling, biocompatibility and overall consumer satisfaction. Given the market’s sensitivity to better products, FibroGen’s dermal filler program aims to produce a product that has the advantages of natural human collagen, avoids the disadvantages of allergic reactions and attendant allergy testing, and has performance benefits comparable to hyaluronic acid.

Recombinant human collagen: new approach to cosmetic dermal fillers

Using proprietary technologies that enable the production of properly formed collagens based on human DNA sequences, FibroGen is developing FG-5030, a highly cross-linked, fully synthetic human collagen (type III). FibroGen's preclinical research demonstrates that FG-5030 has comparable persistence to hyaluronic acid. FG-5030 represents a filler with attributes of classical collagen fillers (e.g., ease of administration) with the added benefits of a fully synthetic human collagen (no skin test expected) and comparable persistence to currently marketed filler products.